• The reports were submitted by the Hyderabad based firm, following a trial on children.
  • As of now ZyCoV-D stands to be the only vaccine which has received the EUA allowance for application on children of 12 years and above.
  • The government has said that 900 million doses have been circulated throughout the country since the beginning of the regulatory process in January this year.

On Saturday, the Bharat Biotech International Limited, the developer of the Covaxin against Covid-19, submitted data regarding its dose trial on children, to the Drugs Controller General of India (DCGI). Dr. Krishna Ella, the chairman and managing director of the Hyderabad based firm has said, “We have submitted the data from trials on volunteers in the age group of 2-18 to the DCGI.”

The new development stands ahead of the organization completing its phase 2/3 trials of the Covaxin on kids last month. The drug regulator was to receive the data regarding the development from Bharat Biotech “very soon”. Presently, children below 18 do not stand to be eligible for participating in the nationwide vaccination drive against the Covid-19 pandemic.

ZyCoV-D happens to be the only vaccine which can be used for people aged 12 and above, among the six vaccines which have received the Emergency Use Authorization (EUA) from the DCGI. The jab of this second indigenous vaccine against the Covid-19 virus has been prepared by the Zydus Cadila of Ahmedabad.

The government is yet to announce a countrywide vaccination drive for children below 18 years of age. Amidst the trigger of a third wave approaching, the reopening of schools in several states has been an addition. The scenario suggests that the sooner an all inclusive vaccination drive is conducted, the lesser the perils of the situation going out of hand.

The Union health ministry’s control panel has maintained that a total number of 900 million doses of the Covid-19 vaccines have been regulated throughout the country since the beginning of the process earlier on January 16 this year.